Compare Infosys Limited (INFY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Smith & Nephew plc — how do they compare? Infosys Limited trades at $10.8 (market cap $41.74B), while Smith & Nephew plc trades at $27.06 (market cap $11.10B). The key difference: Infosys Limited is far larger — about 3.8× Smith & Nephew plc's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Smith & Nephew plc for 120 Days on average.
| INFY | SNN | |
|---|---|---|
Market Cap | $41.74B | $11.10B |
Volume | 31,354,285 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $20.22 | $37.17 |
52-Week Low | $10.49 | $26.42 |
Typical Hold Time | 27 Days | 120 Days |
Enterprise Value | $39.48B | $14.13B |
Dividend Yield | 4.89% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
